Ibere Pharmaceuticals
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBER research report →
Companywww.iberepharma.com
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
- CEO
- Osagie O. Imasogie
- HQ
- Philadelphia, PA, US
Price Chart
Valuation
- Market Cap
- $175.60M
- P/E
- 74.91
- P/S
- 0.00
- P/B
- 0.92
- EV/EBITDA
- -49.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2.46%
- ROIC
- -0.73%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $1.56M · 0.00%
- EPS
- $0.34 · 0.00%
- Op Income
- $-1,004,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $10.75
- 52W Low
- $9.75
- 50D MA
- $10.14
- 200D MA
- $9.95
- Beta
- 0.00
- Avg Volume
- 84.33K
Get TickerSpark's AI analysis on IBER
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 21 | Vollmer Louis J. | buy | 10,000 |
| Feb 25, 21 | Kerekes Zoltan | other | 3,350,000 |
| Feb 25, 21 | PIPV Capital LLC | other | 3,350,000 |
| Feb 25, 21 | IMASOGIE OSAGIE O | other | 3,350,000 |
| Feb 25, 21 | Vollmer Louis J. | other | 25,000 |
| Feb 25, 21 | Gray Lisa M. | other | 3,350,000 |
| Feb 25, 21 | UKWU HENRIETTA | other | 25,000 |
| Feb 25, 21 | Jones Elaine V | other | 25,000 |
| Feb 25, 21 | Johnson Calvin B. | other | 25,000 |
Our IBER Coverage
We haven't published any research on IBER yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IBER Report →